Genedrive PLC Hep C data presentation at EASL
11 Abril 2017 - 3:01AM
RNS Non-Regulatory
TIDMGDR
Genedrive PLC
11 April 2017
For release: 11 April 2017
genedrive plc ("genedrive" or the "Company")
Hepatitis C Assay performance data accepted for presentation at
the International Liver Confrence (EASL) , April 19-23 in
Amsterdam
genedrive plc, the molecular diagnostics company, will be
showcasing its molecular Genedrive(R) HCV ID Kit and Genedrive(R)
platform at the International Liver Conference taking place in
Amsterdam from 19(th) -23(rd) April 2017. Clinical validation data
for Genedrive(R) HCV ID Kit will be presented at the meeting by Dr
Darragh Duffy from the Institut Pasteur, Paris.
The Genedrive(R) HCV ID Kit is a qualitative HCV assay,
providing results within 90 minutes. The assay is designed for use
in a decentralised testing environment and is performed on the
company's portable molecular diagnostics platform. The assay is
performed directly from a small volume of plasma (25ul) and does
not require a separate viral extraction process . The Genedrive(R)
HCV assay recently demonstrated sensitivity of greater than 99% and
specificity of 100% when compared to the Abbott Molecular RealTime
HCV Assay.
"The Genedrive(R) HCV assay will allow decentralised
laboratories to provide affordable onsite molecular testing for HCV
that aligns with recent WHO testing guidelines," said David Budd,
Chief Executive Officer of genedrive plc. "With the wider
availability of generic direct acting antiviral agents, the drive
in resource limited countries is to cost effectively identify and
treat individuals with Hepatitis C. We believe that with the
performance achieved by the Genedrive(R) HCV assay, there is an
opportunity to play a very meaningful role in this strategy."
The company has recently submitted the Genedrive(R) HCV ID Kit
for CE certification under the EU Medical Devices Directive. Anyone
wishing to receive more information on the assay at launch can
register their interest at
https://www.genedrive.com/assays/hcv-assay.php.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel
+44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) platform and MTB/RIF assay has been
launched in India.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
About Hepatitis C
Hepatitis C is an international public health challenge,
comparable to other major communicable diseases, including HIV,
tuberculosis and malaria. It is estimated that 150-200 million
people, or approximately 3% of the world's population, are living
with chronic hepatitis C, and more than 350,000 people die yearly
from hepatitis C related diseases. In 2016, WHO published the first
global health sector strategy on Hepatitis with a goal of
eliminating viral hepatitis as a major public health threat by
2030. New oral, well-tolerated treatment regimens can achieve cure
rates of over 90% however access to rapid, inexpensive and accurate
diagnostics are a critical bottleneck that must be addressed to
eradicate Hepatitis C.
Further details on the PoC-HCV project can be found at
http://www.poc-hcv.eu/index.php
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALIFVISLILLID
(END) Dow Jones Newswires
April 11, 2017 02:01 ET (06:01 GMT)
Epistem (LSE:EHP)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Epistem (LSE:EHP)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024